Early Stages of Schizophrenia
March 2005 – Vol 7 – No. 1
State of the art
The treatment of schizophrenia: from premorbid manifestations to the first episode of psychosis
Michael Davidson, MD; Asaf Caspi, MD; Shlomo Noy, MD, PhD
Basic research
Early biomarkers of psychosis
Robert Freedman, MD; Randal Ross, MD; Sherry Leonard, PhD; Marina Myles-Worsley, PhD; Catherine E. Adams, PhD; Merilyne Waldo, PhD; Jason Tregellas, PhD; Laura Martin, MD; Ann Olincy, MD; Jody Tanabe, MD; Michael A. Kisley, PhD; Sharon Hunter, PhD; Karen E. Stevens, PhD
Cognitive impairment as a risk factor for psychosis
Abraham Reichenberg, PhD
Pharmacological aspects
Treating early psychosis: who, what, and when?
Barbara A. Cornblatt, PhD; MBA; Andrea M. Auther, PhD
Poster
Functional neuroimaging in first-episode psychosis
Mihai D. Gheorghe, MD; PhD; A. V. Baloescu, MD; Gabriella Grigorescu, MA; A. Petrescu, MD
Clinical research
Toward a world consensus on prevention of schizophrenia
Jim Van Os, MD, PhD; Philippe Delespaul, MA, PhD
Environmental risk factors for psychosis
Kimberlie Dean, MBBS, MRCPsych; Robin M. Murray, MD, DSc
Interpreting the association between cannabis use and increased risk for schizophrenia
Mark Weiser , MD; Shlomo Noy, MD; PhD